share_log

通化金马(000766.SZ):新药琥珀八氢氨吖啶片现已完成揭盲、统计分析报告与临床试验总结报告

Tonghua Jinma (000766.SZ): The new drug amber octahydroaminoacridine tablets have now completed investigation, statistical analysis reports and clinical trial summary reports

Gelonghui Finance ·  May 30 04:17

Gelonghui May 30丨Tonghua Jinma (000766.SZ) held a performance briefing on May 29, 2024 to discuss “Can new drug submissions be detected as soon as possible at the Drug Evaluation Center of the State Drug Administration?” The company replied that the company's new drug, amber octahydroaminoacridine tablets, has now completed the investigation, statistical analysis report, and clinical trial summary report. The next step is to submit a marketing application for the new drug to CDE. Currently, in accordance with CDE related requirements, the company is proceeding normally according to the established work plan.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment